CORE LABS INC (CLB)
(Delayed Data from NYSE)
$16.53 USD
-0.46 (-2.71%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $16.54 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CLB 16.53 -0.46(-2.71%)
Will CLB be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CLB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLB
Kinder Morgan (KMI) Beats on Q1 Earnings, Hikes Dividend
Sunoco (SUN) Proceeds With Strategic Portfolio Optimization
CLB: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Core Laboratories (CLB) a New Strong Buy Stock
Earnings Preview: Core Laboratories (CLB) Q1 Earnings Expected to Decline
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Other News for CLB
CORE LAB REPORTS FIRST QUARTER 2024 RESULTS
Core Laboratories: Q1 Earnings Snapshot
CLB Stock Earnings: Core Laboratories Beats EPS, Beats Revenue for Q1 2024
Core Laboratories Non-GAAP EPS of $0.07 misses by $0.08, revenue of $129.6M beats by $5.14M
Core Laboratories sees Q2 EPS 19c-23c, consensus 21c